レストレスレッグス症候群（むずむず脚症候群：RLS）は、ウィリスエクボム病（WED）とも呼ばれ、神経系の一部の障害であり、脚に影響を及ぼし、脚を動かしたいという衝動を引き起こします。 症状には、かゆみ、痛み、不気味な不快感、ふくらはぎや脚のけいれんなどがあります。素因には年齢が含まれます。 治療には、筋弛緩薬、睡眠薬、麻薬が含まれます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Axim Biotechnologies Inc
Bioprojet SCR
Hisamitsu Pharmaceutical Co Inc
Luye Pharma Group Ltd
Omeros Corp
Relmada Therapeutics Inc
Seelos Therapeutics, Inc.
Vifor Pharma Ltd
Restless Legs Syndrome - Drug Profiles
(cannabidiol + dronabinol) - Drug Profile
Product Description
Mechanism Of Action
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
History of Events
esmethadone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-03009 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ropinirole hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 15, 2021: Luye Pharma Group: Clinical trial application submitted in the U.S. for the group's new drug LY03009
Jan 04, 2021: Luye Pharma Group: LY03009 commenced phase I clinical trial in Australia
Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Restless Legs Syndrome, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, 2022
Restless Legs Syndrome - Pipeline by Bioprojet SCR, 2022
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022
Restless Legs Syndrome - Pipeline by Luye Pharma Group Ltd, 2022
Restless Legs Syndrome - Pipeline by Omeros Corp, 2022
Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, 2022
Restless Legs Syndrome - Pipeline by Seelos Therapeutics, Inc., 2022
Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, 2022
Restless Legs Syndrome - Dormant Projects, 2022
Restless Legs Syndrome - Discontinued Products, 2022
List of Figures
Number of Products under Development for Restless Legs Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Types, 2022
